ONC‑392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD‑1/PD‑L1 Inhibitors

Trial status:Recruiting
Trial ID:
PRESERVE-003
NCT ID:
NCT05671510
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
OncoC4, Inc.
Collaborator:
BioNTech SE
Recruiting

Trial Details

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.

Medical Condition
  • Lung Cancer
    • Study Drug
  • Gotistobart
    • See more
  • Docetaxel
    • Phase
    Phase 3
    Type
    Interventional
    Estimated Enrolment
    600
    Estimated Trial Date
    Jun 2023 - Jun 2026

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No
    Inclusion and Exclusion Criteria
    Inclusion criteria

      Inclusion Criteria (Major criteria):

    1. Adult (≥ 18 years), all genders, capable of signing informed consent.
    2. Histologically- or cytologically- confirmed diagnosis of metastatic squamous NSCLC, metastasis can be regional lymph nodes or distant organs.
    3. Radiographic progression after treatment with the most recent line of treatment being either 3a or 3b:
      1. At least 12 weeks of PD-1/PD-L1 inhibitor in combination with platinum-based chemotherapy;
      2. Prior treatment with at least 2 cycles of a platinum-based chemotherapy, followed by at least 12 weeks of standard doses of PD-1 or PD-L1 inhibitor-based immunotherapy.

        3. Antibodies against CTLA-4, LAG-3, TIGIT, VEGF or VEGFR in combination with PD-1/PD-L1 inhibitor are allowed.

    4. At least one measurable tumor lesion according to RECIST 1.1.
    5. ECOG score of 0 or 1.
    6. Adequate organ functions. Serum LDH level ≤ 2xULN.
    7. Life expectancy ≥ 3 months.

      8. Exclusion Criteria (Major criteria):

    8. Cancer treatment related AEs have not recovered to NCI CTCAE grade≤ 1 except endocrinopathy.
    9. Last anti-PD-1/PD-L1 dosing within 28 days prior to first dose of study treatment.
    10. Receiving systemic steroid therapy with \>10 mg/day prednisone or equivalent within 7 days prior to the first dose of study treatment.
    11. Having documented actionable mutations or genomic alterations in any of the following genes: EGFR, ALK, ROS1, HER2, MET, BRAF, RET or NTRK;. Exception: KRAS mutations are not excluded.
    12. Patients who have symptomatic brain metastasis. Palliative radiotherapy or radiosurgery to brain metastasis within 14 days of the first dose of study drug.
    13. Active GI disease, including peptic ulcer disease, pancreatitis, diverticulitis, or inflammatory bowel disease.
    14. Active interstitial lung disease (ILD) or non-infectious pneumonitis.
    15. Active infections with IV antibiotics within 14 days prior to first dose of study treatment.
    16. Impaired heart function.

    Trial Locations

    Location
    Status
    Location
    XCancer/Dothan Hematology & Oncology - 1114
    Dothan, Alabama, United States, 36303
    Status
    Recruiting
    Location
    Genesis Cancer and Blood Institute - 1123
    Russellville, Arkansas, United States, 72801
    Status
    Recruiting
    Location
    The Oncology Institute (TOI) Clinical Research - 1109
    Cerritos, California, United States, 90703
    Status
    Recruiting
    Location
    Emad Ibrahim MD Inc. - 1147
    Redlands, California, United States, 92373
    Status
    Recruiting
    Location
    UC Davis Comprehensive Cancer Center - 1103
    Sacramento, California, United States, 95817
    Status
    Recruiting
    Location
    Bass Medical Group - 1155
    Walnut Creek, California, United States, 94598
    Status
    Recruiting
    Go to page